Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about Y-MABS THERAPEUTICS, INC.
05/19Y-mAbs Therapeutics Appoints President Thomas Gad Interim CEO
MT
05/19Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/10Wedbush Adjusts Price Target for Y-mAbs Therapeutics to $21 From $28, Maintains Outperf..
MT
05/10TRANSCRIPT : Y-mAbs Therapeutics, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/09Y-MABS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/09Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments
AQ
05/09Y-mAbs Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
05/03Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022
AQ
04/28Wedbush Cuts Y-mAbs Therapeutics' Price Target to $28 From $36, Adjusting Nivatrotamab,..
MT
04/27Y MABS THERAPEUTICS : mAbs Announces Executive Management Changes and Provides 2022 Revenu..
PU
04/27Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Finan..
AQ
04/27Y-mAbs Announces Executive Management Changes and Provides 2022 Revenue Guidance and Fi..
AQ
04/27Y-mAbs Therapeutics, Inc. Announces Executive Changes
CI
04/27Y-mAbs Therapeutics, Inc. Announces Management Changes
CI
04/27Y-mAbs Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022
CI
04/08Y-mAbs Announces Presentation of SADA Technology at AACR
AQ
04/04Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA
AQ
04/01Y-mAbs Therapeutics Shares Rise 10% After Resubmitting Biologics License Application
DJ
04/01Y-mAbs Therapeutics Says It Has Resubmitted Application for Investigational Cancer Trea..
MT
04/01Y MABS THERAPEUTICS : mAbs Announces Submission of Omburtamab Biologics License Applicatio..
PU
04/01Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/01Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA
AQ
04/01Y-mAbs Therapeutics, Inc. Announces Submission of Omburtamab Biologics License Applicat..
CI
03/01Y-MABS THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
02/28HC Wainwright Adjusts Y-mAbs Therapeutics' Price Target to $63 from $68, Keeps Buy Rati..
MT
02/25Wedbush Adjusts Y-mAbs Therapeutics Price Target to $36 From $52, Maintains Outperform ..
MT
02/25TRANSCRIPT : Y-mAbs Therapeutics, Inc., 2021 Earnings Call, Feb 25, 2022
CI
02/25Y MABS THERAPEUTICS : mAbs Reports Fourth Quarter and Full ear 2021 Financial Results and ..
PU
02/24Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q4 Revenue $9.6M, vs. Street Est of $10..
MT
02/24Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate..
AQ
02/24Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31,..
CI
02/17Y-mAbs to Announce 2021 Financial and Operating Results on February 24, 2022
AQ
02/14Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab
AQ
02/11Top Midday Gainers
MT
02/11Y-mAbs Therapeutics Shares Rise 28% After FDA Meeting
DJ
02/11Y-mAbs Therapeutics Expects to Resubmit Application for Omburtamab by End of Q1; Shares..
MT
02/11Y-mAbs Therapeutics Completes Pre-BLA Meeting With FDA
DJ
02/11Y MABS THERAPEUTICS : mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab..
PU
02/11Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
02/11Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab
AQ
02/11Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab
CI
02/08INSIDER SELL : Y-mabs Therapeutics
MT
02/01Morgan Stanley Adjusts Y-mAbs Therapeutics Price Target to $15 From $25, Maintains Equa..
MT
01/25INSIDER SELL : Y-mabs Therapeutics
MT
01/11TRANSCRIPT : Y-mAbs Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Confere..
CI
01/05Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
AQ
01/03JPMorgan Adjusts Y-mAbs Therapeutics' Price Target to $27 from $30, Keeps Neutral Ratin..
MT
2021Y MABS THERAPEUTICS : Management Change/Compensation - Form 8-K
PU
2021Y-mAbs Therapeutics, Inc. Announces Appointment of Sue Smith as Chief Commercial Office..
CI
2021Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statement..
AQ
2021TRANSCRIPT : Y-mAbs Therapeutics, Inc. - Special Call
CI
2021UPDATE - Y-mAbs Announces Pipeline Update
GL
2021Y MABS THERAPEUTICS : mAbs Announces Pipeline Update - Form 8-K
PU
2021Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Y-mAbs Announces Pipeline Update
AQ
2021INSIDER SELL : Y-mAbs Therapeutics
MT
2021Y-mAbs Hosting Virtual Research and Development Day
GL
2021Y-mAbs Hosting Virtual Research and Development Day
GL
2021INSIDER SELL : Y-mAbs Therapeutics
MT
2021INSIDER SELL : Y-mAbs Therapeutics
MT
2021Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statement..
AQ
2021Y-mAbs Therapeutics, Inc. Announces Executive Changes
CI
2021Y-mAbs Therapeutics Downgraded, Price Target Cut at JPMorgan
MT
2021JPMorgan Cuts Y-mAbs Therapeutics to Neutral From Overweight, Price Target to $30 From ..
MT
2021TRANSCRIPT : Y-mAbs Therapeutics, Inc., Q3 2021 Earnings Call, Nov 05, 2021
CI
2021Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments - Fo..
PU
2021Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q3 Revenue $9M, vs. Street Est of $10.9..
MT
2021Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments
AQ
2021Y-MABS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
2021Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
CI
2021Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neur..
PU
2021Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neur..
AQ
2021Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neur..
CI
2021Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021
AQ
1  2  3  4  5  6Next
Upcoming event on Y-MABS THERAPEUTICS, INC.